TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
TEVA PHARMACEUTICAL INDUSTRIES LTD
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$41.31−0.19 (-0.46%)
Close on Oct 19, 2026
- Market cap
- $48.13B
- P/E (TTM)
- 68.9
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
51.8%+5.4 pts over 5 years
Operating margin
12.5%+33.9 pts over 5 years
Net margin
8.2%+32.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +4.3% | +5.0% | +0.7% | -1.3% | |
| Gross profit | +10.8% | +8.6% | +3.0% | -2.4% | |
| Operating income | – | – | – | -4.3% | |
| Net income | – | – | – | -1.2% | |
| EPS, diluted | – | – | – | -4.0% | |
| Free cash flow | +53.3% | +3.3% | +12.5% | -13.3% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 1.0% | -33.3% | 21.2% | |
| Return on assets | 0.4% | -7.4% | 3.5% | |
| Current ratio | 0.93 | 0.99 | 1.04 | |
| Interest coverage | 3.9× | -4.0× | 2.4× | |
| Inventory turnover | 2.3× | 2.0× | 2.7× | |
| Capex to revenue | 4.1% | 3.5% | 2.9% | |
| Diluted shares | 0M | 1.09B | 1.16B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Teva Pharmaceutical Industries generated $6.65B from operations and spent $2.64B on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$6.65B
Used
$2.64B
Capital expenditure$2.64B100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin8.2%
×Asset turnover0.43×
×Equity multiplier6.03×
=Return on equity, FY202521.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 8.2% | 0.43× | 6.03× | 21.2% |
| FY2024 | -9.9% | 0.40× | 6.43× | -25.5% |
| FY2023 | -3.5% | 0.36× | 5.71× | -7.3% |
| FY2022 | -16.4% | 0.33× | 5.07× | -27.1% |
| FY2021 | 2.6% | 0.32× | 4.84× | 4.1% |
| FY2020 | -24.0% | 0.31× | 4.50× | -33.3% |
| FY2019 | -5.9% | 0.29× | 4.12× | -7.0% |
| FY2018 | -11.8% | 0.28× | 4.09× | -13.4% |
| FY2017 | -74.4% | 0.27× | 3.23× | -64.2% |
| FY2016 | 1.5% | 0.30× | 2.33× | 1.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$1.41B
- Cash generatingOperating cash flow above zero$1.65B
- Return on assets improvedROA up on the prior year-3.8% → 3.6%
- Earnings backed by cashOperating cash flow above net income$1.65B vs $1.41B
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.98 → 1.04
- No dilutionShare count did not rise1.13B → 1.16B
- Gross margin improvedGross margin up on the prior year48.74% → 51.79%
- More efficientAsset turnover rose0.38 → 0.44